Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG

Journal of Immunology

Volumn 162, Issue 5, 1999, Pages 2982-2989

  Bartemes, Kathleen R ^a   McKinney, Shannon ^a   Gleich, Gerald J ^a   Kita, Hirohito ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; HEXANOL; ICOSANOID; IMMUNOGLOBULIN G; INTERLEUKIN 5; ISRAPAFANT; LEUKOTRIENE C4; PERTUSSIS TOXIN; PHOSPHOLIPASE; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR;

ALLERGIC DISEASE; ARTICLE; ASTHMA; AUTOCRINE EFFECT; CELL ACTIVATION; CONTROLLED STUDY; DEGRANULATION; EFFECTOR CELL; ENZYME INHIBITION; EOSINOPHIL; HUMAN; HUMAN CELL; ICOSANOID METABOLISM; IMMUNOPATHOGENESIS; INFLAMMATION; MEDIATOR RELEASE; PARACRINE SIGNALING; PRIORITY JOURNAL;

EICOSANOIDS; EOSINOPHILS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-5; PERTUSSIS TOXIN; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; PYRIDINIUM COMPOUNDS; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE; VIRULENCE FACTORS, BORDETELLA;

EID: 0033105811     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Butterfield, J. H., K. L. Leiferman, and G. J. Gleich. 1995. Eosinophil-associated diseases. In Samter's Immunologic Diseases, Vol. 1. M. M. Frank, K. F. Austen, H. N. Claman, and E. R. Unanue, eds. Little, Brown and Company, Boston, pp. 501-527.
2. Kita, H., C. Adolphson, and G. J. Gleich. Biology of eosinophils. 1998. In Allergy: Principles and Practice, 5th Ed. E. Middleton, Jr., C. E. Reed, E. F. Ellis, N. F. Adkinson, Jr., J. W. Yunginger, and W. W. Busse. Mosby-Year Book, St. Louis, pp. 242-260.
3. Lee, T.-c., D. J. Lenihan, B. Malone, L. L. Roddy, and S. I. Wasserman. 1984. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J. Biol. Chem. 259:5526.
4. Sedgwick, J. B., R. F. Vrtis, M. F. Gourley, and W. W. Busse. 1988. Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. J. Allergy Clin. Immunol. 81:876.
5. Abu-Ghazaleh, R. I., T. Fujisawa, J. Mestecky, R. A. Kyle, and G. J. Gleich. 1989. IgA-induced eosinophil degranulation. J. Immunol. 142:2393.
6. Filley, W. V., K. E. Holley, G. M. Kephart, and G. J. Gleich. 1982. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 2:11.
7. Leiferman, K. M., S. J. Ackerman, H. A. Sampson, H. S. Haugen, P. Y. Venencie, G. J. Gleich. 1985. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N. Engl. J. Med. 313:282.
8. Krogel, C., T. Yukawa, G. Dent, P. Chanez, K. F. Chung, and P. J. Barnes. 1988. Platelet activating factor induces eosinophil peroxidase release from human eosinophils. Immunology 64:559.
9. Horie, S., G. J. Gleich, and H. Kita. 1996. Cytokines directly induce degranulation and superoxide production from human eosinophils. J. Allergy Clin. Immunol. 98:371.
10. Kernen, P., M. P. Wymann, V. von Tschamer, D. A. Deranleau, P.-C. Tai, C. J. Spry, C. A. Dahinden, and M. Baggiolini. 1991. Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils. J. Clin. Invest. 87:2012.
11. Prescott, S. M., G. A. Zimmerman, and T. M. McIntyre. 1990. Platelet-activating factor. J. Biol. Chem. 265:17381.
12. Cromwell, O., A. J. Wardlaw, A. Champion, R. Moqbel, D. Osei, and A. B. Kay. 1990. IgG-dependent generation of platelet-activating factor by normal and low density human eosinophils. J. Immunol. 145:3862.
13. Izumi, T., and T. Shimizu. 1995. Platelet-activating factor receptor: gene expression and signal transduction. Biochim. Biophys. Acta 1259:317.
14. Hanahan, D. J. 1986. Platelet activating factor: a biologically active phosphoglyceride. Annu. Rev. Biochem. 55:483.
15. Barnes, P. J. 1991. Platelet activating factor and asthma. Ann. NY Acad. Sci. 629:193.
16. Wardlaw, A. J., R. Moqbel, O. Cromwell, and A. B. Kay. 1986. Platelet-activating factor: a potent chemotactic and chemokinetic factor for human eosinophils. J. Clin. Invest. 78:1701.
17. Kroegel, C., T. Yukawa, G. Dent, P. Venge, K. F. Chung, and P. J. Barnes. 1989. Stimulation of degranulation from human eosinophils by platelet-activating factor. J. Immunol. 142:3518.
18. Zoratti, E. M., J. B. Sedgwick, R. R. Vrtis, and W. W. Busse. 1991. The effect of platelet-activating factor on the generation of superoxide anion in human eosinophils and neutrophils. J. Allergy Clin. Immunol. 88:749.
19. 4 synthesis by purified human eosinophils. Prostaglandins 34:205.
20. Ide, M., D. Weiler, H. Kita, and G. J. Gleich. 1994. Ammonium chloride exposure inhibits cytokine-mediated eosinophil survival. J. Immunol. Methods 168: 187.
21. 2 integrin in the activation of eosinophils stimulated by IgG. J. Immunol. 155:2631.
22. Horie, S., and H. Kita. 1994. CD11b/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet-activating factor. J. Immunol. 152:5457.
23. van der Bruggen, T., P. T. M. Kok, J. A. M. Raaijmakers, J. W. J. Lammers, and L. Koenderman. 1994. Cooperation between Fcγ receptor II and complement receptor type 3 during activation of platelet-activating factor release by cytokine-primed human eosinophils. J. Immunol. 153:2729.
24. Kita, H., R. I. Abu-Ghazaleh, S. Sur, and G. J. Gleich. 1995. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J. Immunol. 154:4749.
25. Weller, P. F., S. J. Ackerman, A. Nicholson-Weller, and A. M. Dvorak. 1989. Cytoplasmic lipid bodies of human neutrophilic leukocytes. Am. J. Pathol. 135:947.
26. Moss, J., and M. Vaughan. 1988. ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. Adv. Enzymol. 61:303.
27. Daëron, M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15:203.
28. Devos, R., G. Plaetinck, S. Cornelis, Y. Guisez, J. Van der Heyden, and J. Tavernier. 1995. Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease. J. Leukocyte Biol. 57:813.
29. Sugiura, T., K. Mabuchi, A. Ojima-Uchiyama, Y. Masuzawa, N. N. Cheng, T. Fukuda, S. Makino, and K. Waku. 1992. Synthesis and action of PAF in human eosinophils. J. Lipid Mediat. 5:151.
30. Terashita, Z. I., Y. Imura, M. Takatani, S. Tsushima, and K. Nishikawa. 1987. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J. Pharmacol. Exp. Ther. 242:263.
31. Grigoriadis, G., and A. G. Stewart. 1991. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N-trimethyl)-hexanolamine: an analogue of platelet-activating factor with partial agonist activity. Br. J. Pharmacol. 104:171.
32. Terasawa, M., H. Aratani, M. Setoguchi, and T. Tahara. 1990. Pharmacological actions of Y-24180. I. A potent and specific antagonist of platelet-activating factor. Prostaglandins 40:553.
33. Bozza, P. T., W. Yu, J. F. Penrose, E. S. Morgan, A. M. Dvorak, and P. F. Weller. 1997. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J. Exp. Med. 186:909.
34. Weller, P. F., R. A. Monahan-Earley, H. F. Dvorak, and A. M. Dvorak. 1991. Cytoplasmic lipid bodies of human eosinophils: subcellular isolation and analysis of arachidonate incorporation. Am. J. Pathol. 138:141.
35. Snyder, F.1994. Metabolic processing of PAF. Clin. Rev. Allergy 12:309.
36. 2: dissociation constants for calcium, substrate, products, and competitive inhibitors. Biochemistry 30:7306.
37. 2. J. Clin. Invest. 91:2118.
38. Ojima-Uchiyama, A., Y. Masuzawa, T. Sugiura, K. Waku, T. Fukuda, and S. Makino. 1991. Production of platelet-activating factor by normodense and hypodense eosinophils. Lipids 26:1200.
39. Marcheselli, V. L., M. J. Rossowska, M.-T. Domingo, P. Braquet, and N. G. Bazan. 1990. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J. Biol. Chem. 265:9140.
40. Hwang, S. B., M. H. Lam, and S. S. Pong. 1986. Ionic and GTP regulation of binding of platelet-activating factor to receptors and platelet-activating factor-induced activation of GTPase in rabbit platelet membranes. J. Biol. Chem. 261: 532.
41. Svetlov, S., and S. Nigam. 1993. Evidence for the presence of specific high affinity cytosolic binding sites for platelet-activating factor in human neutrophils. Biochem. Biophys. Res. Commun. 190:162.
42. Miwa, M., T. Miyake, T. Yamanaka, J. Sugatani, Y. Suzuki, S. Sakata, Y. Araki, and M. Matsumoto. 1988. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J. Clin. Invest. 82:1983.
43. Freitag, A., R. M. Watson, G. Matsos, C. Eastwood, and P. M. O'Byrne. 1993. Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. Thorax 48:594.
44. Kuitert, L. M., K. P. Hui, S. Uthayarkumar, W. Burke, A. C. Newland, S. Uden, and N. C. Barnes. 1993. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am. Rev. Respir. Dis. 147:82.
45. Kagoshima, M., N. Tomomatsu, Y. Iwahisa, S. Yamaguchi, M. Matsuura, Y. Kawakami, and M. Terasawa. 1997. Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs. Inflamm. Res. 46:147.
46. Hozawa, S., Y. Haruta, S. Ishioka, and M. Yamakido. 1995. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am. J. Respir. Crit. Care Med. 152:1198.